Kenvue Inc. (NYSE:KVUE) Shares Sold by Boston Financial Mangement LLC

Boston Financial Mangement LLC trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 2.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 196,906 shares of the company’s stock after selling 4,457 shares during the period. Boston Financial Mangement LLC’s holdings in Kenvue were worth $4,204,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Grove Bank & Trust increased its position in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue in the 4th quarter worth about $29,000. Fortitude Family Office LLC lifted its position in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in Kenvue during the 3rd quarter valued at about $35,000. Finally, Versant Capital Management Inc boosted its stake in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on KVUE. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group cut their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Barclays lowered their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average price target of $23.00.

Kenvue Stock Performance

NYSE:KVUE opened at $22.26 on Thursday. The company has a 50-day moving average of $21.28 and a 200-day moving average of $22.14. The firm has a market cap of $42.68 billion, a price-to-earnings ratio of 42.00, a price-to-earnings-growth ratio of 2.57 and a beta of 1.45. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.68%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.